Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Indinavir sulfate Clear all
Completed Phase 1 Interventional

A Study of L-735,524 in HIV-Positive Children and Adolescents

NCT00002351
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
10 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

NCT00000922
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

NCT00002387
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 4 Interventional

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

NCT00002179
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Redwood City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Not applicable Interventional

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

NCT00000861
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy

NCT00000850
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Sargramostim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 26, 2026, 2:29 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002440
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • New Haven, Connecticut • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

NCT00000870
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

NCT00002208
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

NCT00001058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection

NCT00001443
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
indinavir (MK-0639)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 2:29 AM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

NCT00002241
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

NCT00000944
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

NCT00002209
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
CPI-1189
Drug
Lead sponsor
Centaur Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

A Study of Indinavir Taken With or Without DMP 266

NCT00002393
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Augusta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Not applicable Interventional

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

NCT00002407
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

NCT00000877
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
8
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

NCT00000916
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Hydroxyurea, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
34
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

NCT00001566
View directory record Official record
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 26, 2026, 2:29 AM EDT
Terminated Not applicable Interventional

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

NCT00006326
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Delavirdine mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Not applicable Interventional

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

NCT00002236
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

NCT00002371
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
5
States / cities
Torrance, California • Tampa, Florida • Stony Brook, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Sep 26, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Interaction With HIV Antiretroviral Agents

NCT02556268
View directory record Official record
Conditions
HIV-DDI
Interventions
Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 26, 2026, 2:29 AM EDT